InBev Biopharmaceutical
Precision fermentation for commercial scale animal-free proteins
About InBev Biopharmaceutical
BioBrew is a corporate venture and separate R&D division of the world's largest brewer, Anheuser-Busch InBev (AB InBev), focused on bringing advanced precision fermentation to a commercial scale. Launched in 2019 by a small team and backed by ZX Ventures, the investment and innovation group of AB InBev, BioBrew was founded by Patrick O'Riordan, who also serves as the Global Head of BioBrew. O'Riordan, who holds a PhD in Food Science & Technology, was previously a co-founding partner at ZX Ventures.
The company leverages AB InBev's centuries of expertise in large-scale yeast fermentation to produce animal-free proteins and other sustainable bio-products. The business model centers on utilizing precision fermentation, a process where microorganisms like yeast are programmed to create specific products, such as proteins, instead of alcohol. This allows BioBrew to address the growing demand for alternative proteins driven by ecological concerns and the need for more efficient food systems. By applying its parent company's extensive knowledge and infrastructure in scaled fermentation, BioBrew aims to overcome the production capacity limitations faced by many smaller biotech firms in the alternative protein market.
BioBrew's primary service is to scale up the production of these bio-products for partners. A key example is its partnership with The EVERY Company, announced in April 2021, to ramp up the production of animal-free egg proteins. The technology works by programming yeast cells to deliver specific proteins, which are then cultivated in large fermentation tanks and fed with sugar. The resulting product can be purified into a protein powder for use as an ingredient by the food industry. AB InBev claims that one full BioBrew fermentation tank can produce a food equivalent of 5,000 cows or 300,000 chickens. The company operates a pilot plant for proteins in Germany and plans to build larger, separate production units.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.3/100
- Industry
- Food
- Sector
- Fermentation, Alternative Protein, precision fermentation
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2026 | $28M | $206M | Xiner Technology · Deep Intelligent Pharma | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
BioColorFermentation-derived natural colors for the food industry. |
Copenhagen, Denmark | Operational | 7 | — | — |
TerrafermaAI-powered platform for sustainable protein biomanufacturing. |
San Francisco, United States | Operational | |||
The Protein ExpressFungal precision fermentation platform for scalable protein production |
Wageningen, Netherlands | Operational | |||
NoietPrecision fermentation for alternative protein development |
Milan, Italy | Operational | |||
LevyaSustainable fats and oils from precision fermentation |
Brazil | Operational | |||
FoodHQA food innovation hub connecting partners to build a sustainable food system and develop agri-food leaders via case study competitions |
Palmerston North, New Zealand | Operational | |||
PentasweetFermentation-derived sweet protein for sugar reduction solutions. |
Vilnius, Lithuania | Operational | |||
KMYeast Science & TechnologyProprietary Kluyveromyces yeast for food and pharmaceutical applications |
Haikou, China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
InBev Biopharmaceutical in its local ecosystem
The InBev Biopharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Deep Intelligent Pharma- XTXiner Technology
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about InBev Biopharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InBev Biopharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










